Cargando…

Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure

Chronic heart failure (CHF) represents a major cause of hospitalization and death. Recent evidence shows that novel biomarkers such as soluble suppression of tumorigenicity (sST2), growth-differentiation factor-15 (GDF-15), soluble urokinase plasminogen activator receptor (suPAR) and heart-type fatt...

Descripción completa

Detalles Bibliográficos
Autores principales: Jirak, Peter, Fejzic, Dzeneta, Paar, Vera, Wernly, Bernhard, Pistulli, Rudin, Rohm, Ilonka, Jung, Christian, Hoppe, Uta C, Schulze, P Christian, Lichtenauer, Michael, Yilmaz, Atilla, Kretzschmar, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6289366/
https://www.ncbi.nlm.nih.gov/pubmed/29239349
http://dx.doi.org/10.1038/aps.2017.167
_version_ 1783379949967638528
author Jirak, Peter
Fejzic, Dzeneta
Paar, Vera
Wernly, Bernhard
Pistulli, Rudin
Rohm, Ilonka
Jung, Christian
Hoppe, Uta C
Schulze, P Christian
Lichtenauer, Michael
Yilmaz, Atilla
Kretzschmar, Daniel
author_facet Jirak, Peter
Fejzic, Dzeneta
Paar, Vera
Wernly, Bernhard
Pistulli, Rudin
Rohm, Ilonka
Jung, Christian
Hoppe, Uta C
Schulze, P Christian
Lichtenauer, Michael
Yilmaz, Atilla
Kretzschmar, Daniel
author_sort Jirak, Peter
collection PubMed
description Chronic heart failure (CHF) represents a major cause of hospitalization and death. Recent evidence shows that novel biomarkers such as soluble suppression of tumorigenicity (sST2), growth-differentiation factor-15 (GDF-15), soluble urokinase plasminogen activator receptor (suPAR) and heart-type fatty acid binding protein (H-FABP) are correlated with inflammatory and ischemic responses in CHF patients. In this study we examined the effects of Ivabradine that inhibited the hyperpolarization-activated cyclic nucleotide-gated channel (HCN channel, also called funny current I(f)), thereby leading to selective heart rate reduction and improved myocardial oxygen supply on the cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in 50 CHF patients at the University Hospital of Jena. Patients were divided into three groups based on the etiology of CHF: dilated cardiomyopathy (DCM, n=20), ischemic cardiomyopathy (ICM, n=20) and hypertensive cardiomyopathy (HCM, n=10). The patients were administered Ivabradine (5 mg, bid for 3 months, and 7.5 mg bid for further 3 months). Analyses of cardiovascular biomarkers were performed at baseline as well as at 3- and 6-month follow-ups. At 6-month follow-up, GDF-15 levels were significantly reduced compared to baseline levels (P=0.0215), indicating a reduction in the progress of cardiac remodeling. H-FABP concentration was significantly lower in DCM patients compared to ICM (1.89 vs 3.24 μg/mL) and HCM patients (1.89 vs 3.80 μg/mL), and decreased over the 6-month follow-up (P=0.0151). suPAR median levels remained elevated, implying major ongoing inflammatory processes. As shown by significant decreases in GDF-15 and H-FABP levels, a reduction in ventricular remodeling and sub-clinical ischemia could be assumed. However, markers of hemodynamic stress (sST2) and inflammation (suPAR) showed no change or progression after 6 months of Ivabradine treatment in CHF patients. Further studies are necessary to validate the clinical applicability of these novel cardiovascular biomarkers.
format Online
Article
Text
id pubmed-6289366
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-62893662019-07-01 Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure Jirak, Peter Fejzic, Dzeneta Paar, Vera Wernly, Bernhard Pistulli, Rudin Rohm, Ilonka Jung, Christian Hoppe, Uta C Schulze, P Christian Lichtenauer, Michael Yilmaz, Atilla Kretzschmar, Daniel Acta Pharmacol Sin Article Chronic heart failure (CHF) represents a major cause of hospitalization and death. Recent evidence shows that novel biomarkers such as soluble suppression of tumorigenicity (sST2), growth-differentiation factor-15 (GDF-15), soluble urokinase plasminogen activator receptor (suPAR) and heart-type fatty acid binding protein (H-FABP) are correlated with inflammatory and ischemic responses in CHF patients. In this study we examined the effects of Ivabradine that inhibited the hyperpolarization-activated cyclic nucleotide-gated channel (HCN channel, also called funny current I(f)), thereby leading to selective heart rate reduction and improved myocardial oxygen supply on the cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in 50 CHF patients at the University Hospital of Jena. Patients were divided into three groups based on the etiology of CHF: dilated cardiomyopathy (DCM, n=20), ischemic cardiomyopathy (ICM, n=20) and hypertensive cardiomyopathy (HCM, n=10). The patients were administered Ivabradine (5 mg, bid for 3 months, and 7.5 mg bid for further 3 months). Analyses of cardiovascular biomarkers were performed at baseline as well as at 3- and 6-month follow-ups. At 6-month follow-up, GDF-15 levels were significantly reduced compared to baseline levels (P=0.0215), indicating a reduction in the progress of cardiac remodeling. H-FABP concentration was significantly lower in DCM patients compared to ICM (1.89 vs 3.24 μg/mL) and HCM patients (1.89 vs 3.80 μg/mL), and decreased over the 6-month follow-up (P=0.0151). suPAR median levels remained elevated, implying major ongoing inflammatory processes. As shown by significant decreases in GDF-15 and H-FABP levels, a reduction in ventricular remodeling and sub-clinical ischemia could be assumed. However, markers of hemodynamic stress (sST2) and inflammation (suPAR) showed no change or progression after 6 months of Ivabradine treatment in CHF patients. Further studies are necessary to validate the clinical applicability of these novel cardiovascular biomarkers. Nature Publishing Group UK 2017-12-14 2018-07 /pmc/articles/PMC6289366/ /pubmed/29239349 http://dx.doi.org/10.1038/aps.2017.167 Text en © CPS and SIMM 2018 This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/
spellingShingle Article
Jirak, Peter
Fejzic, Dzeneta
Paar, Vera
Wernly, Bernhard
Pistulli, Rudin
Rohm, Ilonka
Jung, Christian
Hoppe, Uta C
Schulze, P Christian
Lichtenauer, Michael
Yilmaz, Atilla
Kretzschmar, Daniel
Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure
title Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure
title_full Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure
title_fullStr Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure
title_full_unstemmed Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure
title_short Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure
title_sort influences of ivabradine treatment on serum levels of cardiac biomarkers sst2, gdf-15, supar and h-fabp in patients with chronic heart failure
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6289366/
https://www.ncbi.nlm.nih.gov/pubmed/29239349
http://dx.doi.org/10.1038/aps.2017.167
work_keys_str_mv AT jirakpeter influencesofivabradinetreatmentonserumlevelsofcardiacbiomarkerssst2gdf15suparandhfabpinpatientswithchronicheartfailure
AT fejzicdzeneta influencesofivabradinetreatmentonserumlevelsofcardiacbiomarkerssst2gdf15suparandhfabpinpatientswithchronicheartfailure
AT paarvera influencesofivabradinetreatmentonserumlevelsofcardiacbiomarkerssst2gdf15suparandhfabpinpatientswithchronicheartfailure
AT wernlybernhard influencesofivabradinetreatmentonserumlevelsofcardiacbiomarkerssst2gdf15suparandhfabpinpatientswithchronicheartfailure
AT pistullirudin influencesofivabradinetreatmentonserumlevelsofcardiacbiomarkerssst2gdf15suparandhfabpinpatientswithchronicheartfailure
AT rohmilonka influencesofivabradinetreatmentonserumlevelsofcardiacbiomarkerssst2gdf15suparandhfabpinpatientswithchronicheartfailure
AT jungchristian influencesofivabradinetreatmentonserumlevelsofcardiacbiomarkerssst2gdf15suparandhfabpinpatientswithchronicheartfailure
AT hoppeutac influencesofivabradinetreatmentonserumlevelsofcardiacbiomarkerssst2gdf15suparandhfabpinpatientswithchronicheartfailure
AT schulzepchristian influencesofivabradinetreatmentonserumlevelsofcardiacbiomarkerssst2gdf15suparandhfabpinpatientswithchronicheartfailure
AT lichtenauermichael influencesofivabradinetreatmentonserumlevelsofcardiacbiomarkerssst2gdf15suparandhfabpinpatientswithchronicheartfailure
AT yilmazatilla influencesofivabradinetreatmentonserumlevelsofcardiacbiomarkerssst2gdf15suparandhfabpinpatientswithchronicheartfailure
AT kretzschmardaniel influencesofivabradinetreatmentonserumlevelsofcardiacbiomarkerssst2gdf15suparandhfabpinpatientswithchronicheartfailure